title: [Early phase II study of amrubicin (SM-5887) for superficial bladder cancer: a dose-finding study for intravesical chemotherapy].
abstract: An early phase II study (dose-finding study) of amrubicin hydrochloride for superficial bladder cancer was conducted. Amrubicin was dissolved in 30 ml of physiological saline and injected intravesically for 6 consecutive days. The drug solution was retained for 2 hours. Patients were randomly assigned to four groups, which were administered amrubicin at doses of 30, 60, 90, and 120 mg/day, respectively. Of 65 patients registered in this study, 63 were eligible and assessable for toxicities, and 55 assessable for efficacy. The response rate at each dose level was 50.0% (7PRs/14 patients) at 30 mg/day, 53.3% (8 PRs/15) at 60 mg/day, 61.5% (2 CRs + 6 PRs/13) at 90 mg/day, and 69.2% (2 CRs + 7 PRs/13) at 120 mg/day, respectively. These data suggests that the efficacy was related to the doses of amrubicin. The major toxicities were cystic irritabilities, such as micturition pain, pollakisuria and hematuria. These toxicities were related to the doses of amrubicin. Their incidence and the severity were not high compared with those reported about other anthracyclines such as doxorubicin and epirubicin. The optimal dose of amrubicin was estimated to be 90 to 120 mg/day in the intravesical treatment for superficial bladder cancer once a day for 6 consecutive days.
authors.affiliation: Dept. of Urology, Okayama University Medical School.
authors.forename: T
authors.initials: T
authors.lastname: Tsushima
authors.forename: K
authors.initials: K
authors.lastname: Kobashi
authors.forename: N
authors.initials: N
authors.lastname: Akebi
authors.forename: T
authors.initials: T
authors.lastname: Yamato
authors.forename: T
authors.initials: T
authors.lastname: Asahi
authors.forename: Y
authors.initials: Y
authors.lastname: Maki
authors.forename: H
authors.initials: H
authors.lastname: Ohmori
mesh_terms: D000283:Administration, Intravesical; D000368:Aged; D018943:Anthracyclines / Q000008:administration & dosage* / Q000009:adverse effects; D000970:Antineoplastic Agents / Q000008:administration & dosage* / Q000009:adverse effects; D004334:Drug Administration Schedule; D005260:Female; D006417:Hematuria / Q000139:chemically induced; D006801:Humans; D008297:Male; D008875:Middle Aged; D010146:Pain / Q000209:etiology; D001749:Urinary Bladder Neoplasms / Q000188:drug therapy* / Q000503:physiopathology; D014554:Urination
chemical_list: D018943:Anthracyclines; D000970:Antineoplastic Agents; C055866:amrubicin